drugset / Trial / NCT00124527
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.
Timeline
- Start
- 2005-03-31
- Primary completion
- 2006-08-31
- Completion
- 2006-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | irofulven | Small molecule | — | — |